Skip to main content

Table 1 Patients’ baseline characteristics according to age

From: Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results

Characteristic Age <70 years (n = 1297) Age ≥70 years (n = 480) Age <75 years (n = 1571) Age ≥75 years (n = 206)
Gender, n (%)     
 Male 811 (63) 297 (62) 985 (63) 123 (60)
 Female 486 (37) 183 (38) 586 (37) 83 (40)
Median age, years (range) 61 (19–69) 73 (70–100) 63 (19–74) 77 (75–100)
ECOG performance status, n (%)     
 0 503 (39) 153 (32) 598 (38) 58 (28)
 1 647 (50) 251 (52) 785 (50) 113 (55)
 2 119 (9) 56 (12) 147 (9) 28 (14)
 3 4 (<1) 11 (2) 11 (1) 4 (2)
 4 0 1 (<1) 1 (<1) 0
 Missing 24 (2) 8 (2) 29 (2) 3 (1)
Metastatic site, n (%) a     
 Liver 935 (72) 332 (69) 1130 (72) 137 (67)
 Lung 357 (28) 133 (28) 434 (28) 56 (27)
 Bone 47 (4) 10 (2) 53 (3) 4 (2)
 Other 350 (27) 107 (22) 408 (26) 49 (24)
No. of metastatic sites, n (%)     
 1 824 (64) 321 (67) 1007 (64) 138 (67)
 >1 405 (31) 124 (26) 476 (30) 53 (26)
 Missing 68 (5) 35 (7) 88 (6) 15 (7)
Local recurrence, n (%) 585 (51) 220 (51) 711 (51) 94 (50)
Median CEA, ng/mL (range) 20.9 (0–14 671) 20.7 (0.1–25305) 20.4 (0–25 305) 25.6 (0.1–6848)
Surgical removal of primary tumour, n (%) 1210 (93) 442 (92) 1464 (93) 188 (91)
Prior radiotherapy, % 18 14 18 12
Prior chemotherapy, %     
Adjuvant 67 68 67 66
Neoadjuvant 11 11 10 12
Systolic hypertension, %     
Mild 26 28 27 25
Moderate 6 8 6 10
Severe 1 1 1 1
Diaystolic hypertension, %     
Mild 17 14 17 12
Moderate 2 3 2 3
Severe 1 1 1 0
  1. CEA, carcinoembryonic antigen; ECOG, Eastern Cooperative Oncology Group. aPatients could have >1 metastatic site.